Webinar :Register now for webinar on 'Trade BankNifty in just 15 minutes a day' - By Asmita Patel
you are here: HomeNewsTrendsHealth
Last Updated : Oct 20, 2020 11:11 AM IST | Source: Reuters

Coronavirus vaccine update: China's Sinovac is safe, says Brazil's leading research institute

São Paulo's Butantan Institute, one of Brazil's leading biomedical research centers, which is carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.

Reuters

An experimental coronavirus vaccine developed by China's Sinovac Biotech appeared to be safe in a late-stage clinical trial in Brazil, preliminary results showed on Monday.

São Paulo's Butantan Institute, one of Brazil's leading biomedical research centers, which is carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.

Close

But Butantan director Dimas Covas said data on how effective the vaccine is will not be released until the trial is completed on all of the 13,000 volunteers.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"The first results of the clinical study conducted in Brazil prove that among all the vaccines tested in the country, CoronaVac is the safest, the one with the best and most promising rates," São Paulo Governor João Doria told reporters.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

The result is only preliminary and researchers will keep monitoring the participants in the on-going trial, Covas said. It's the first set of results of Sinovac's Phase 3 global trials, which are also being conducted in Turkey and Indonesia.

Covas said there were no severe adverse reactions to the vaccine, with 20% of the volunteers reporting mild pain from the injection while 15% reported headaches after the first dose, dropping to 10% for the second. Less than 5% reported nausea or tiredness, and even less had muscle aches, he said.

São Paulo state health secretary Jean Gorinchteyn said the vaccine appeared to produce protective anti-bodies. The state hopes to obtain regulatory approval for CoronaVac by the end of the year to start inoculating its population early in 2021, in what could the first vaccination programs in the Americas.

São Paulo signed a deal with Sinovac to buy 60 million doses by the end of February.

Sinovac wanted Brazil as a testing ground because it has been one of the global hotbeds of the virus, although cases are 43% off their peak of nearly 70,000 new cases a day in late July.

Brazil has reported more than 5.2 million COVID-19 cases since the pandemic began, the world's third most-affected country after the United States and India.

AstraZeneca PLC and Oxford University are nearing an analysis of their UK coronavirus vaccine trial. Pfizer Inc has said it could provide an early analysis of its trial this month, and Moderna Inc may announce its results in November. Russia's Gamaleya Institute may provide an analysis of its vaccine in the next month.

Competing candidates developed by AstraZeneca and Johnson & Johnson have had their trials halted in the United States due to safety issues.

Vaccines are considered as essential tools to curb the rampaging virus, which has killed over 1 million people globally. Brazil is also hosting a Phase 3 trial for AstraZeneca's vaccine candidate, while Johnson & Johnson said last month it aims to expand its final-stage human trials there.

CoronaVac uses inactivated vaccine technology, a traditional method that uses killed virus that cannot replicate in human cells to trigger an immune response.

Experts have warned that the safety of inactivated coronavirus vaccine candidates should be observed over longer periods, as some other inactivated vaccines had led to disease enhancement effect, where vaccine-triggered antibodies, instead of offering protection, could worsen infections when people became exposed to a virus after inoculation.
First Published on Oct 20, 2020 09:43 am
Sections